Globus Medical (NYSE:GMED) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $66.0, with a high estimate of $85.00 and a low estimate of $60.00. Marking an increase of 3.94%, the current average surpasses the previous average price target of $63.50.

Deciphering Analyst Ratings: An In-Depth Analysis

The analysis of recent analyst actions sheds light on the perception of Globus Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Globus Medical's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Globus Medical analyst ratings.

All You Need to Know About Globus Medical

Financial Milestones: Globus Medical's Journey

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Globus Medical displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 124.6%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Globus Medical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 2.44%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Globus Medical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.37%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Globus Medical's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.29%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.13.

How Are Analyst Ratings Determined?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.